SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 129.98 |
| Enterprise Value ($M) | 111.75 |
| Book Value ($M) | 57.11 |
| Book Value / Share | 0.59 |
| Price / Book | 2.37 |
| NCAV ($M) | 48.56 |
| NCAV / Share | 0.52 |
| Price / NCAV | 2.68 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.25 |
| Return on Assets (ROA) | -0.13 |
| Return on Equity (ROE) | -0.24 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.09 |
| Current Ratio | 5.26 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 106.89 |
| Assets | 115.44 |
| Liabilities | 58.34 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 27.86 |
| Operating Income | -14.89 |
| Net Income | -14.23 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 49.60 |
| Cash from Investing | -46.25 |
| Cash from Financing | 0.55 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Bristol Myers Squibb Co | 2.06 | -61.32 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 55,104 | 326,174 | 16.89 | |
| 65,354 | 250,059 | 26.14 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CDTX – Cidara Therapeutics, Inc. | CELU – Celularity Inc. |
| CELZ – Creative Medical Technology Holdings, Inc. | CGTX – Cognition Therapeutics, Inc. |
| CING – Cingulate Inc. |
Financial data and stock pages provided by
Fintel.io